

Drug Price Transparency Manufacturer Reporting Training Webinar

Drug Price Transparency Program Team
Division of Financial Regulation
Feb. 16, 2023



Department of Consumer
and Business Services

Agenda



Annual price increase reporting

New drug reporting

iReg users and contacts



iReg is our
reporting
system



60-day price increase notice reporting

Correspondence and requests for information



Trade secret claims

Billings and assessments

Annual price increase reporting

When to file?



- Reporting threshold:
 - Increase in weighted average wholesale acquisition cost (WAC) of **10 percent** or more, **AND**
 - WAC for drug is **\$100** or more for a 30-day supply (or course of treatment lasting less than one month).
- Due date: If required, 2022 reports are due **March 15, 2023**.
- **Example:** Drug Z costs \$500 during 2021. The price is increased to \$575 on May 1, 2022. The average price for 2022 is \$550.34 (120 days at \$500 and 245 days at \$575). The increase is 10 percent or more, so a report is required.

Annual price increase reporting

- Start annual price increase filing.
- Enter filing year and National Drug Code (NDC).
- Enter trade name and chemical name if not populated.

Insurance iReg - Drug Prices - Annual Filings - Filings

Entity Name: ENTITY NAME

Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day

Filings

Details

Show All

10 records per page

Create/Filing Date

Showing 0 to 0 of 0 entries

Create New Filing

New Drugs Annual Filings Correspondence 60-Day Billings

Filings

Details

Start Annual Drug Filing

Filing Year: *

NDC: *

Trade Name: *

Chemical Name: *

Next Cancel

Annual price increase reporting

- Complete the report following our user guide.



New Drugs Annual Filings Correspondence 60-Day Billings Instruct

Filings Details

Drug Price Increase Filing Details

Filing Status: In Progress

* Filing Year:

* NDC:

* Trade Name:

* Chemical Name:

Generic Name(s):

For the NDC:

* Net Increase Percent:

* Introductory Price: Trade Secret?

* Price on January 1st:

* Price on December 31st:

* Highest Wholesale Acquisition Cost (WAC):


* Lowest Wholesale Acquisition Cost (WAC):

* Average Wholesale Acquisition Cost (WAC): Trade Secret?

* Dosage: Trade Secret?

Annual price increase reporting

- Complete the report following our user guide.



The screenshot shows a web form for annual price increase reporting. It includes a required field for 'Date on Market' with a calendar icon, a large text area for 'Increase factors', and a 'Trade Secret?' dropdown menu currently set to 'Not Set'.



Increase factors compliance tip: Report clear and specific information. If company did not use any drug comparisons for determining the price increase, clearly confirm in writing that no comparison was used *and* report what the company did use for setting the increased price.

Annual price increase reporting

- Complete the report following our user guide.



| R&D Costs Using: | | Direct Costs: | |
|----------------------------------|-----------------------|---------------------------------------|-----------------------|
| * International Public Funds: | <input type="text"/> | * Manufacturing: | <input type="text"/> |
| | Trade Secret? Not Set | | Trade Secret? Not Set |
| * USA Federal Public Funds: | <input type="text"/> | * Marketing: | <input type="text"/> |
| | Trade Secret? Not Set | | Trade Secret? Not Set |
| * All States Public Funds: | <input type="text"/> | * Distribution: | <input type="text"/> |
| | Trade Secret? Not Set | | Trade Secret? Not Set |
| * All Local Public Funds: | <input type="text"/> | * Safety and Effectiveness: | <input type="text"/> |
| | Trade Secret? Not Set | | Trade Secret? Not Set |
| * Public Funds Sources and Uses: | <input type="text"/> | * Total Sales Revenue: | <input type="text"/> |
| | | | Trade Secret? Not Set |
| | | * Profit from Drug: | <input type="text"/> |
| | | | Trade Secret? Not Set |
| | | * Other Relevant Pricing Information: | <input type="text"/> |
| | | | Trade Secret? Not Set |

Annual price increase reporting

- Complete the report following our user guide.



Non US Prices:

* ☐ We only sell in the US Trade Secret? Not Set ▼

| | Country | Price |
|-------------|----------------------|----------------------|
| Country 1: | <input type="text"/> | <input type="text"/> |
| Country 2: | <input type="text"/> | <input type="text"/> |
| Country 3: | <input type="text"/> | <input type="text"/> |
| Country 4: | <input type="text"/> | <input type="text"/> |
| Country 5: | <input type="text"/> | <input type="text"/> |
| Country 6: | <input type="text"/> | <input type="text"/> |
| Country 7: | <input type="text"/> | <input type="text"/> |
| Country 8: | <input type="text"/> | <input type="text"/> |
| Country 9: | <input type="text"/> | <input type="text"/> |
| Country 10: | <input type="text"/> | <input type="text"/> |

5-Year Net Annual Increases:

* Trade Secret? Not Set ▼

| | % Increase | |
|------|----------------------|--|
| 2022 | <input type="text"/> | <input type="checkbox"/> Not on Market |
| 2021 | <input type="text"/> | <input type="checkbox"/> Not on Market |
| 2020 | <input type="text"/> | <input type="checkbox"/> Not on Market |
| 2019 | <input type="text"/> | <input type="checkbox"/> Not on Market |
| 2018 | <input type="text"/> | <input type="checkbox"/> Not on Market |

Patient Assistance Programs:

10 ▼ records per page Search:

| Program Name | Participant Count | Value of Assistance |
|----------------------------|-------------------|---------------------|
| No data available in table | | |

Showing 0 to 0 of 0 entries ← Prev

[Add Assistance Program](#)

Annual price increase reporting

- Complete the report following our user guide.

Add Assistance Program

* Program Name:

* Program Type:

* Number of Participants: Trade Secret?

* Value of Assistance: Trade Secret?

* Refills: Trade Secret?

* Time Period: Trade Secret?




* Eligibility Criteria: Trade Secret?

* Eligibility Verification Process: Trade Secret?

Annual price increase reporting

- Complete the report following our user guide.
- If a document is needed to explain a data element, click the “Attach New Document” button.
- Identify the section of the report or choose “Other Supporting Documentation.”
- The reason for the inclusion information will appear on the transparency site.



The screenshot displays a web form titled "Add Document" with a sub-section "Attach Supporting Document". The form includes the following fields and controls:

- Document Type:** A dropdown menu currently set to "Other Supporting Documental" with a red asterisk indicating it is a required field.
- Reason for Inclusion:** A large text area containing the placeholder text "Description and reason for document" and a red asterisk.
- Document:** A file upload section with a "Choose File" button and the filename "20211208-D...-agenda.pdf" followed by a red asterisk.
- Trade Secret?:** A dropdown menu set to "Not Set" with a red asterisk.
- Buttons:** "Submit" and "Cancel" buttons at the bottom of the form.

Annual price increase reporting

- Once completed, you will certify to submit the report.

Documents:

10 records per page

Search:

| Doc Type | Reason for Inclusion | TS? | Justification | Document |
|-----------------------------|-----------------------------|-----|---------------|---|
| Patient Assistance Programs | Additional PAP information. | No | | View Info View Original |

Showing 1 to 1 of 1 entries

[← Previous](#)

[Attach New Document](#)

[Continue To Certification](#) [Save Progress](#) [Cancel](#) [Start/Open Correspondence](#) [Delete Filing](#)



When you view a submitted report, you will only have the link to its correspondence.

NDC: 00111222333

Trade Name: Trade name

Chemical Name: Chemical name

Certification

Certifier's Name: *

☐ I, the undersigned authorized filer, hereby certify that the filing submitted complies with the applicable State law and regulations, Bulletins, filing requirements and reporting guidance set forth on the Department of Consumer and Business Services' web site. I further certify the filing is not false or misleading in any material respect and that I am authorized to sign and submit this certificate on behalf of the Company identified (hereinafter Company).

I understand that the Department of Consumer and Business Services will rely on this certificate and, should it be determined that this filing is materially false or misleading, appropriate action including civil penalties, as authorized by law, will be taken by the Department of Consumer and Business Services against the Company.

[Certify](#) [Cancel](#)

Annual price increase reporting

Tips and reminders:



- Reports for 2022 are due March 15, 2023.
- Only file reports that are required. See formula for average price and examples in user guide.
- Report the specific information requested.
- Report accurate and complete information.
- Delete in progress reports that are not required.
- If there are missing reports due in prior years, submit as soon as possible to avoid or reduce penalties.

New specialty drug reporting

When to file?



- Reporting threshold:
 - Price exceeds \$670 for a 30-day supply, or a course of treatment lasting less than 1 month.
- Due date: If required, due within 30 days of launch for sale in the U.S.
- If a drug meets the reporting threshold, report on each NDC being introduced to the U.S. market.

New specialty drug reporting

- Start new specialty drug filing.
- Enter NDC, trade name, and chemical name.

Insurance iReg - Drug Prices - New Drugs - Filings

Entity Name: ENTITY NAME

Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day

Filings

Details

Show All

10 records per page

Create/Filing Date

Showing 0 to 0 of 0 entries

Create New Filing

Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day Billings

Filings

Details

Start New Drug Filing

NDC: *

Trade Name: *

Chemical Name: *


Next Cancel



Reminder for generic drug reports: Enter the trade name of the NDC being reported. Do not report the brand name of a competing product.

New specialty drug reporting

- Complete the report following our user guide.



The screenshot shows a web form for reporting on a new specialty drug. It is divided into two main sections. The top section contains two required fields, each marked with a red asterisk: 'Trade Name:' with a text input field containing 'Trade name', and 'Chemical Name:' with a text input field containing 'Chemical name'. The bottom section contains a required field marked with a red asterisk: 'Marketing Description:' with a large text area. To the right of the 'Marketing Description:' label is a 'Trade Secret?' label followed by a yellow dropdown menu currently set to 'Not Set'.



Compliance tip for marketing description:

Report marketing activities and the amounts spent and include:

- Direct-to-consumer marketing, such as paid advertising
- Marketing to promote the drug to physicians

Generic drugs: If drug is not marketed, tell us there is no marketing and no spending.

New specialty drug reporting

- Complete the report following our user guide.

| | | | |
|-------------------------------------|----------------------|---------------|-----------|
| * Wholesale Acquisition Cost (WAC): | <input type="text"/> | Trade Secret? | Not Set ▼ |
| * Dosage: | <input type="text"/> | Trade Secret? | Not Set ▼ |
| * Pricing Methodology: | <input type="text"/> | Trade Secret? | Not Set ▼ |



Compliance tip for pricing methodology: Report all major financial and nonfinancial factors that influenced the price.

Generic drugs: Provide comparison information *or* confirm no comparison was used and report what guided pricing.

New specialty drug reporting

- Complete the report following our user guide.

| | |
|-----------------------------------|----------------------|
| * FDA Priority or Breakthrough: | <input type="text"/> |
| Acquisition Cost: | <input type="text"/> |
| Required if the drug was acquired | |
| Acquisition Date: | <input type="text"/> |
| Required if the drug was acquired | |
| Trade Secret? | Not Set |



Report Acquisition Cost and Date *only* if applicable.

| | |
|--|----------------------|
| * Estimated Avg. Number of Patients per Month: | <input type="text"/> |
| Patients per Month Description: | <input type="text"/> |
| Trade Secret? | Not Set |

New specialty drug reporting

- Complete the report following our user guide.

R&D Costs Using:

* International Public Funds:

Trade Secret? Not Set

* USA Federal Public Funds:

Trade Secret? Not Set

* All States Public Funds:

Trade Secret? Not Set

* All Local Public Funds:

Trade Secret? Not Set

* Public Funds Sources and Uses:

Trade Secret? Not Set

Documents:

10 records per pageSearch:

| Doc Type | Reason for Inclusion | TS? | Justification | Document |
|--|--|-----|---------------|---|
| FDA Priority or Breakthrough Designation | FDA information on breakthrough therapy. | No | | <div>View Info</div> <div>View Original</div> |

Showing 1 to 1 of 1 entries

← Previous1Next →

Attach New Document

Continue To Certification

Save Progress

Cancel

Start/Open Correspondence

Delete Filing

New specialty drug reporting

Tips and reminders:

- Reports are due within 30 days of market availability.
- Report the specific information requested.
- Report accurate and complete information.
- Only file reports that are required.
- Delete in progress reports that are not required.
- If there are missing reports due in prior years, submit as soon as possible to avoid or reduce penalties.

iReg users and contacts

- Manufacturers are responsible for keeping their company information up to date.
- Certain notices are only received by contacts, not users.
 - It is important to have the correct users as contacts.
- Make sure your email system is not blocking or quarantining communications from iReg (emails ending with “.gov”).

iReg users and contacts

- Users: Each user may also have permissions for the type of reports processed. This allows the user to view, create, edit, or submit reports for specified categories.

The screenshot shows the 'Users' tab in the iReg application. The interface includes a navigation bar with 'Main', 'Users', and 'Contacts' tabs, and buttons for 'Instructions' and 'Log out'. On the left, there is a sidebar with 'User List' (highlighted) and 'User Detail'. The main content area displays a table of users with columns for Logon ID, First Name, Last Name, Email Address, and Phone Number. A single user, 'FLASTNAX', is listed with the email 'rx.prices@dcbs.oregon.gov' and phone number '503-947-7200'. The table is set to show 10 records per page. Below the table, there are buttons for 'Add User', 'Edit User', and 'Remove User'.

| Logon ID | First Name | Last Name | Email Address | Phone Number |
|----------|------------|-----------|---------------------------|--------------|
| FLASTNAX | First & | Last Name | rx.prices@dcbs.oregon.gov | 503-947-7200 |

iReg users and contacts

Contacts: List of contacts receiving notices for accounts

The screenshot displays the iReg web application interface, specifically the 'Contacts' section. The top navigation bar includes 'Main', 'Users', and 'Contacts' tabs, along with 'Instructions' and 'Log out' buttons. The left sidebar contains 'Contact List' (highlighted), 'Contact Detail', and 'Contact History'. The main content area shows a 'What is a contact?' help link and a table with columns 'Name Title' and 'Email Address'. A single contact is listed with the name 'First & Last Name, Title' and email 'rx.prices@dcbs.oregon.gov'. Below the table are buttons for 'Add Contact', 'Edit Contact', and 'Remove Contact'. A second, smaller screenshot is overlaid on the bottom right, showing the 'Contact History' view. It features a search bar, a 'Filter' button, and a table with columns 'Date' and 'Subject'. The table lists three entries, all dated '01/06/2022' and '01/05/2022', with subjects related to 'TEST: Oregon Division of Financial Regulation iReg reporting system - Account Updated' and 'Welcome'.

Contacts Interface:

- Navigation: Main, Users, Contacts
- Buttons: Instructions, Log out
- Sidebar: Contact List, Contact Detail, Contact History
- Table Headers: Name Title, Email Address
- Table Data:

| Name Title | Email Address |
|--------------------------|---------------------------|
| First & Last Name, Title | rx.prices@dcbs.oregon.gov |
- Buttons: Add Contact, Edit Contact, Remove Contact

Contact History Interface:

- Navigation: Main, Users, Contacts
- Buttons: Instructions, Log out
- Sidebar: Contact List, Contact Detail, Contact History
- Section: ALL Contacts
- Search: Filter
- Table Headers: Date, Subject
- Table Data:

| Date | Subject |
|------------|---|
| 01/06/2022 | TEST: Oregon Division of Financial Regulation iReg reporting system - Account Updated |
| 01/05/2022 | TEST: Oregon Division of Financial Regulation iReg reporting system - Account Updated |
| 01/05/2022 | TEST: Oregon Division of Financial Regulation iReg reporting system - Welcome |

i Contact history shows prior iReg system notices sent.

iReg users and contacts

Users: access permissions

For every account in iReg, there should be at least one user with the appropriate permissions to adjust contacts and users.

The screenshot displays the 'Application Access' configuration page for 'Financial Regulation'. It features two main sections: 'Financial Regulation' and 'Drug Prices'. Each section has a list of permissions on the left and an 'Application Information' box on the right. At the bottom, there are 'Save' and 'Cancel' buttons.

Application Access:

Financial Regulation

- Registered Entities Administration
- Registered Entities Submission
- Registered Entities View

Manage Users

Application Information:
Includes Tax filings and other Financial Data
For Assistance Contact:
Financial Regulation Section
orinstax.ins@oregon.gov

Drug Prices

- 60-Day Increase Notice ☐
- Annual Drug Price Filings ☐
- New Specialty Drug Filings ☐

☐ **Manage Users**

Application Information:
Drug Price reporting and correspondence by Pharmaceutical Manufacturers
For Assistance Contact:
Drug Price Transparency Program
rx.prices@oregon.gov
503-947-7200

Save **Cancel**

60-day price increase notice reporting

When to file?

- Reporting threshold for **brand-name** drugs:
 - Planned increase of 10 percent or more within the 12-month period prior to the increase date
 - OR
 - A planned increase of \$10,000 or more.
- Reporting threshold for **generic** drugs:
 - Planned increase of 25 percent or more within the 12-month period prior to the increase date
 - AND
 - The increase is \$300 or more.


60-day price increase notice reporting

When to file?


- Due date: If required, the report must be filed at least 60 days prior to the date of the planned increase.
- Exception: This report is not required if the drug is manufactured by four or more companies and meets the criteria listed in ORS 646A.683(4).

60-day price increase notice reporting

- Start 60-day price increase notice filing.
- Enter NDC and date of planned price increase.
 - Add new NDC and enter trade name and chemical name if not populated.



The screenshot shows a software interface with a top navigation bar containing 'New Drugs', 'Annual Filings', 'Correspondence', '60-Day', and 'Billings'. The '60-Day' tab is selected. On the left, a sidebar has 'Filings' and 'Details' buttons, with 'Filings' being active. The main content area has a 'Show All' dropdown, a '10 records per page' selector, and a table header with columns 'Create/Filing Date', 'Trade Name', and 'NDC'. The table body is empty, displaying 'No data available' in a blue bar. Below the table, it says 'Showing 0 to 0 of 0 entries' and there is a 'Create New Filing' button.



The screenshot shows a form titled '60-Day Price Increase Notice'. It contains the following fields and controls:

- NDC:** A text input field containing '45678912300' with a red asterisk indicating it is required.
- Trade Name:** A text input field containing 'Brand name' with a red asterisk.
- Chemical Name:** A text input field containing 'Chemical name' with a red asterisk.
- Add New NDC:** A checkbox that is checked.
- Date Increase Effective:** A date input field containing '06/01/2023' with a calendar icon and a red asterisk.
- Buttons:** 'Next' and 'Cancel' buttons at the bottom.

60-day price increase notice reporting

- Complete the report following our user guide.

Name:

* Year Available in US:

* Current Price (WAC):

Price Increase for this NDC

* New Price (WAC):

* Date Increase Effective:

Trade Secret?

Not Set

▼

Trade Secret?

Not Set

▼

27

60-day price increase notice reporting

- Complete the report following our user guide.

Reason for Price Increase

Change: A chemical change was made.

Improvement: A functional improvement was made.

* Description: Trade Secret?

Other: Use this when the price increase is due to reasons not identified above.

Description: Trade Secret?



If there was no change or improvement to the drug, remember to select “yes” for other reason and provide a description.

Other Relevant Information: Trade Secret?

Correspondence and requests for information



- Correspondence is a way to communicate directly with program staff members regarding a report in iReg.
- This can be used to communicate information or ask questions specific to that report.
- Respond to request for information (RFI) letters in iReg.



Note that iReg correspondence is published to the prescription drug price transparency website when the report status is marked “Filing Complete.”

Correspondence and requests for information

- Correspondence thread for a report can be accessed at the bottom of the report.
- View message box and attachments posted by program staff.



Correspondence and requests for information

- Correspondence tab lists all correspondence.
- Each thread is associated with a report.

New Drugs

Annual Filings

Correspondence

60-Day

Billings

Instructions

Log out

Thread List

Details

Show All

10

 records per page

Search:

| | Start Date | Status | Filing Type | Trade Name | NDC | Rcvd/Sent/New | Attn Date | Attn Party |
|----------------------------------|------------|-----------|-------------|---------------------------|-------------|---------------|-----------|------------|
| <input checked="" type="radio"/> | 01/06/2022 | Submitted | increase | Brand name, if applicable | 00112233445 | 1 / 1 / 1 | | DFR |
| <input type="radio"/> | 01/06/2022 | Submitted | annual | Brand name, if applicable | 00112233445 | 1 / 1 / 1 | | DFR |
| <input type="radio"/> | 01/06/2022 | Submitted | specialty | Brand name, if applicable | 00112233445 | 0 / 1 / 0 | | DFR |

Showing 1 to 3 of 3 entries

← Previous

1

Next →

Correspondence and requests for information

- When responding, select “Add Correspondence.” Provide information in the message box. Attach a document, if needed.

Chemical Name:

01/06/2022 - parrase Other
Reply Due: 02/25/2022 Viewed On: 01/27/2023
Message:

01/06/2022 - flastnax Request for Additional Information
Message: Viewed On: 01/06/2022

[Add Correspondence](#)

New Correspondence

Correspondence Type: *

Message: Trade Secret?

Supporting Document: 2022 public hearing written comments - emails.pdf Trade Secret?

[Post](#) [Cancel](#)

Correspondence and requests for information

Tips and reminders:

- Review due dates for correspondence.
- Make sure your company is not delaying or rejecting emails from iReg (email addresses ending with .gov).
- Email rx.prices@dcbs.oregon.gov if you have questions about how to respond.
- Correspondence is not posted to the transparency site until the report status is set to “Filing Complete.”

Trade secret claims and determinations

Is it a trade secret?

- Is the information *specific*?
- Is there company protocol for protecting the information?
- Is it available anywhere else?
- Is it kept as a secret?

Trade secret claims and determinations

Examples that are not a trade secret:

- Generalized information that is not specific or detailed.
- Common industry knowledge or practice.
- Information available publicly, including anywhere on the web.
- Non-responsive entries such as “0” or “1” or “\$0” answers.
- iReg correspondence message box when only the document contains trade secrets.

Trade secret claims and determinations

Before claiming trade secret, carefully review OAR 836-200-0540 (Information Claimed to be Trade Secret).

Steps when claiming trade secret:

1. Clearly indicate or mark which information is asserted as trade secret.
2. For each piece of information, provide a written explanation that demonstrates all of the listed criteria.

Trade secret claims and determinations

Steps when claiming trade secret (continued):

3. The manufacturer has the burden of proof to establish that information submitted is conditionally exempt from disclosure as a trade secret.
4. Read the entire administrative rule and ORS 192.345.
5. Trade secret determinations are sent securely to contacts using Biscom. Keep contacts updated in iReg.

Trade secret claims and determinations



Common errors:

- Claiming a trade secret for information commonly shared outside the company, such as WAC or dosage.
- Listing common industry practices as trade secret.
- Listing the estimated average number of patients as a trade secret when it is from a source outside the company.
- Claiming public funds used for research and development as trade secret when funding is public information, or entering \$0 and claiming trade secret.

Trade secret claims and determinations

Tips and reminders:

- Reporting information *is* required even when claiming trade secret.
- Report and delineate the specific information that *is* a trade secret from information that is not.
- Burden of proof for trade secret claims is on the manufacturer.
- Do not send trade secret information using standard email.

Billings and assessments

Annual billing information

- Annual billing owed by all reporting manufacturers.
- Amount owed each year:
 - Annual assessment: Each reporting manufacturer owes this fee, currently set at \$400.
 - Reporting assessment: Manufacturers who submitted reports during the billing period owe a fee for each report. The amount varies each year.



Billings and assessments

Annual billing information

- Billing period: Aug. 1 of prior year through July 31 of current year.
- 2023 billing period = Aug. 1, 2022, through July 31, 2023. Reporting assessment is based on new drug and annual increase reports filed during the period.
- Due date: **Oct. 1** each year.
 - 2023 annual billing is due **Oct. 1, 2023**.
- Demand to pay notice: Issued 30 days before due date.
 - Demand to pay notices will be sent via iReg Sept. 1, 2023.



Billings and assessments

- View the Billings tab to see a list of each year's assessment.

Correspondence

60-Day

Billings

10 records per page

| | Year | Status | Amount Billed | Due Date |
|----------------------------------|------|-----------|---------------|------------|
| <input checked="" type="radio"/> | 2022 | COMPLETED | 1187.00 | 10/01/2022 |
| <input type="radio"/> | 2021 | COMPLETED | 400.00 | 10/01/2021 |
| <input type="radio"/> | 2020 | COMPLETED | 1067.00 | 10/01/2020 |
| <input type="radio"/> | 2019 | COMPLETED | 6085.00 | 10/01/2019 |

Showing 1 to 4 of 4 entries



Notices about billings are usually sent through iReg and can be reviewed by viewing all contacts history in the Contacts tab.

Billings and assessments

- Select “Details” to access the voucher and detailed information about the billing.

| | |
|---------------------------|---|
| Year: | <input type="text" value="2020"/> |
| Billing Status: | <input type="text" value="PENDING"/> * |
| Annual Assessment Billed: | <input type="text" value="400.00"/> * |
| Report Assessment Billed: | <input type="text" value="93854.00"/> * |
| Total Amount Billed: | <input type="text" value="94254.00"/> |
| Due Date: | <input type="text" value="10/01/2020"/> * |

10 records per page

| 10 records per page | | | |
|--------------------------------|--------------|-----------------|-----------------|
| NDC | Trade Name | Chemical Name | Filing Type |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| 00002143461 | p_trade_name | p_chemical_name | New Specialty I |
| Showing 1 to 10 of 145 entries | | | |
| ← Previous | | | |
| Print Payment Coupon | | | |



Billings and assessments

- Select “Fiscal Details” to see the financial transactions.

Billing Year: 2020

| Activity Date | Posting Type | Amount | Balance | Annual Assessment Credited | Annual Assessment Balance | Report Assessment Credited | Report Assessment Balance | Interest Credited | Interest Balance |
|---|--------------|----------|---------|----------------------------|---------------------------|----------------------------|---------------------------|-------------------|------------------|
| <input checked="" type="radio"/> 03/22/2022 | 14 | -4284.00 | 0.00 | 400.00 | 0.00 | 3884.00 | 0.00 | 0.00 | 0.00 |
| <input type="radio"/> 03/18/2022 | 11 | 4284.00 | 4284.00 | -400.00 | 400.00 | -3884.00 | 3884.00 | 0.00 | 0.00 |

Billings and assessments

- Debts sent to collections will not reflect the balance available from Accounts Receivable or the Department of Revenue.
- Voucher can no longer be printed from iReg, so contact us if you need a copy for your records.

Insurance iReg - Business Home In Collections | Enforcement Action 4.0
Entity Name: DRUG PRICE TEST CO. User Name: First & Last Name
Home Drug Prices

New Drugs Annual Filings Correspondence 60-Day Billings Instructions Log out

List Details Fiscal Details

10 records per page Filter

| | Year | Status | Amount Billed | Due Date |
|----------------------------------|------|-----------------------|---------------|------------|
| <input checked="" type="radio"/> | 2021 | IN COLLECTIONS (A.R.) | 400.00 | 10/01/2021 |
| <input type="radio"/> | 2020 | COMPLETED | 400.00 | 10/01/2020 |
| <input type="radio"/> | 2019 | COMPLETED | 400.00 | 10/01/2019 |

Showing 1 to 3 of 3 entries

← Previous 1 Next →

Billings and assessments

Tips and reminders:

- Make sure reports submitted are required.
- Check fiscal details for balances and payments posted.
- Include voucher when paying. Mail check payments as instructed on the voucher or call cashiering to pay by credit or debit card.
- Annual billings not paid by the due date will be sent to collections (our accounts receivable unit).
- For debts in collections, we can tell you who to contact for balance and payment options.

Links and resources

Drug Price Transparency (DPT) contacts:

- ❖ Program email: rx.prices@dcbs.oregon.gov; message line 503-947-7200 or 833-210-4560 (toll-free)
- ❖ Sofia Parra, program coordinator: sofia.e.parra@dcbs.oregon.gov; or call directly at 503-983-0447
- ❖ Sally Sylvester, compliance specialist: sally.b.sylvester@dcbs.oregon.gov
- ❖ Cashiering unit (credit or debit card payments): 503-947-7891; available 8 a.m. to 4 p.m. (Monday-Friday)
- iReg reporting system: <https://www4.cbs.state.or.us/exs/ins/ireg/>
- DPT webpage for manufacturers with information and user guide: <https://dfr.oregon.gov/drugtransparency/Pages/manufacturers.aspx>

Links and resources

- DPT main webpage: <https://dfr.oregon.gov/drugtransparency/>
- Oregon Revised Statutes: ORS 646A.680 to 646A.692 (drug price transparency statutes). Click on link and scroll down to referenced statutes.
https://www.oregonlegislature.gov/bills_laws/ors/ors646A.html
- Oregon Administrative Rules: OAR 836-200-0500 through 836-200-0560. Click on link and scroll down to referenced rules.
<https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=3795>
- Bulletin 2020-12: <https://dfr.oregon.gov/laws-rules/Documents/Bulletins/bulletin2020-12.pdf>
- Oregon Revised Statutes: ORS 192.345 (trade secret exemption).
https://www.oregonlegislature.gov/bills_laws/ors/ors192.html

Questions?

Contact DPT program at rx.prices@dcbs.oregon.gov
or contact Sofia Parra (program coordinator) at
sofia.e.parra@dcbs.oregon.gov or 503-983-0447



Department of Consumer
and Business Services